6918 — A Plus Biotechnology Co Share Price
Last trade - 00:00- TWD3.47bn
- TWD3.14bn
- TWD769.59m
- 99
- 40
- 47
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.11 | ||
| Price to Tang. Book | 4.14 | ||
| Price to Free Cashflow | 22.88 | ||
| Price to Sales | 4.51 | ||
| EV to EBITDA | 15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.5% | ||
| Return on Equity | 17.65% | ||
| Operating Margin | 23.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 503.29 | 541.85 | 615.48 | 675.05 | 769.59 | n/a | n/a | 10.18% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +15.68 | -8.66 | +38.4 | -31.28 | +383.82 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
A Plus Biotechnology Co Ltd is a Taiwan-based company mainly engaged in the manufacture and wholesale of trauma and orthopedic products, proxy products and other medical equipment. Trauma products provide stable fixation of various fracture types of bones in various parts until bone healing, including orthopedic internal fixation bone plates, bone nails, bone needles, intramedullary nails, cables, and external fixators. Orthopedic products are used to assist precise correction and fixation, including knee arthritis correction systems, hallux valgus correction systems, and additive manufacturing surgical guide plates. Proxy products include artificial bone replacement, cartilage repair, and cell therapy. Spinal products are used to fix the spine and support the intervertebral height, including spinal fixation systems and spinal intervertebral fusion devices. The products are mainly sold domestically and exported to mainland China, Asia, the United States, and Africa.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 4th, 2009
- Public Since
- January 6th, 2023
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 34,571,000
- Address
- 3F, No.21, Qiaohe Road, Zhonghe District, NEW TAIPEI, 235
- Web
- https://www.aplusbio.com/
- Phone
- +886 222499222
- Contact
- Hsiang-Wei Lo
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 6918
Similar to 6918
Apex Biotechnology
Taiwan Stock Exchange
Wellell
Taiwan Stock Exchange
Bionime
Taiwan Stock Exchange
Bonraybio Co
Taiwan Stock Exchange
CHC Healthcare
Taiwan Stock Exchange
FAQ
As of Today at 19:17 UTC, shares in A Plus Biotechnology Co are trading at TWD100.50. This share price information is delayed by 15 minutes.
Shares in A Plus Biotechnology Co last closed at TWD100.50 and the price had moved by +13.05% over the past 365 days. In terms of relative price strength the A Plus Biotechnology Co share price has outperformed the FTSE Developed Asia Pacific Index by +1.79% over the past year.
There is no consensus recommendation for this security.
Find out moreThe A Plus Biotechnology Co dividend yield is 3.98% based on the trailing twelve month period.
Last year, A Plus Biotechnology Co paid a total dividend of TWD4.00, and it currently has a trailing dividend yield of 3.98%. We do not have any data on when A Plus Biotechnology Co is to next pay dividends.
We do not have data on when A Plus Biotechnology Co is to next pay dividends. The historic dividend yield on A Plus Biotechnology Co shares is currently 3.98%.
To buy shares in A Plus Biotechnology Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD100.50, shares in A Plus Biotechnology Co had a market capitalisation of TWD3.47bn.
Here are the trading details for A Plus Biotechnology Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6918
Based on an overall assessment of its quality, value and momentum A Plus Biotechnology Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like A Plus Biotechnology Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -9.76%.
As of the last closing price of TWD100.50, shares in A Plus Biotechnology Co were trading +4.07% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The A Plus Biotechnology Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD100.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on A Plus Biotechnology Co's directors